Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Diamedica Therapeutics Inc (NQ: DMAC )

1.590 +0.080 (+5.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Diamedica Therapeutics Inc

< Previous 1 2 Next >
DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Present at Credit Suisse 31st Annual Healthcare Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Provides Update on ReMEDy2 Trial
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Present at Lake Street’s 6th Annual Best Ideas Growth Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2022 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Participate in the BTIG Biotechnology Conference 2022
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199
From DiaMedica Therapeutics
Via Business Wire
DiaMedica Therapeutics to Attend the 19th Annual Craig-Hallum Institutional Investor Conference Wednesday, June 1, 2022
From DiaMedica Therapeutics
Via Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2022 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update May 5, 2022
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Fourth Quarter 2021 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Appointment of Dominic Cundari as Chief Commercial Officer
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Present Research at International Stroke Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Appoints Dr. Kirsten Gruis as Chief Medical Officer
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Participation in LifeSci Partners 11th Annual Corporate Access Event
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2021 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Attend the 12th Annual Craig-Hallum Alpha Select Conference November 16, 2021
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Addition of Stroke Recurrence as a Second Independent Primary Endpoint in ReMEDy2 Phase 2/3 AIS Trial
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Report Third Quarter 2021 Financial Results and Provide a Business Update November 11, 2021
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Late Breaking Data from REDUX Phase 2 Trial to be Presented at ASN Kidney Week 2021
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Fast Track Designation Granted to DM199 for the Treatment of Acute Ischemic Stroke
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Closing of $30 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces $30 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.